Skip to main content

Table 3 Crude and adjusted effects of stavudine use on toxicity initiated on HAART

From: A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects

Toxicity

No events

Person

Time (years)

Rate/100 pys*

(95% CI)‡

Crude HR§

(95% CI)‡

Adjusted† HR

(95% CI)‡

Peripheral Neuropathy

Other

d4T-based

61

1454

775.9

12055.5

7.9 (6.0-10.1)

12.1 (7.0-19.5)

1.0

1.53 (1.19-1.98)

1.0

2.02 (1.35-3.03)

Symptomatic hyperlactataemia

Other

d4T-based

12

487

852.3

13690.9

1.4 (0.7-2.5)

3.6 (1.2-7.5)

1.0

2.70 (1.52-4.79)

1.0

2.81 (1.26-6.31)

Lactic acidosis

Other

d4T-based

7

214

848.3

13805.9

0.8 (0.3-1.7)

1.6 (0.4-5.2)

1.0

2.09 (0.99-4.44)

1.0

2.55 (0.81-8.00)

Pancreatitis

Other

d4T-based

1

14

858.9

14126.2

0.1 (0.003-0.6)

0.1 (0.02-2.6)

1.0

0.95 (0.13-7.21)

1.0

0.40 (0.05-3.16)

Lipoatrophy

Other

d4T-based

25

616

834.0

13534.3

3.0 (1.9-4.4)

4.6 (2.1-9.6)

1.0

1.67 (1.12-2.50)

1.0

1.60 (0.92-2.77)

Hypertension

Other

d4T-based

17

167

845.0

13929.0

2.0 (1.2-3.2)

1.2 (0.2-4.0)

1.0

0.66 (0.40-1.08)

1.0

0.83 (0.39-1.78)

Diabetes Mellitus

Other

d4T-based

1

28

859.0

14122.7

0.1 (0.003-0.6)

0.2 (0.02-2.6)

1.0

1.90 (0.26-14.04)

1.0

2.07 (0.28-15.21)

Dyslipidaemia

Other

d4T-based

9

109

856.5

14097.2

1.1 (0.4-2.0)

0.8 (0.2-4.0)

1.0

0.82 (0.41-1.61)

1.0

0.61 (0.27-1.40)

  1. *pys = person years
  2. § HR = hazard ratio estimated from Cox proportional hazard models
  3. ‡ 95% CI = 95% confidence interval
  4. † All models adjusted for age, gender, baseline CD4 count, baseline body mass index and time at which HAART was initiated (either prior to or post October 2007)